Concerning HbA1c, one possible explanation is the trial design, since iDegLira was compared with glargine as add-on to SGLT2i, and both arms followed a treat to target approach; in regard to hypoglycemia incidence, it could be also due to the effects of liraglutide, differences in the insulin dose, as well as in the type of insulin, since lower rates of hypoglycemia have been reported for insulin degludec compared to insulin glargine U-10019,22,23. Here, INS is linked to Hypoglycemia.